Q2YDC9
Gene name |
PDCD2 |
Protein name |
Programmed cell death protein 2 |
Names |
|
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:512079 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q2YDC9
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q2YDC9-F1 | Predicted | AlphaFoldDB |
49 variants for Q2YDC9
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs477568945 | 3 | S>C | No | EVA | |
| rs457917489 | 10 | E>G | No | EVA | |
| rs472431198 | 22 | L>P | No | EVA | |
| rs461949826 | 23 | R>G | No | EVA | |
| rs441753206 | 25 | E>G | No | EVA | |
| rs476743867 | 26 | Q>E | No | EVA | |
| rs456601755 | 26 | Q>L | No | EVA | |
| rs433171606 | 27 | F>L | No | EVA | |
| rs454467618 | 29 | S>R | No | EVA | |
| rs434264925 | 30 | K>R | No | EVA | |
| rs448666294 | 31 | V>G | No | EVA | |
| rs438155275 | 32 | G>A | No | EVA | |
| rs449676068 | 33 | G>S | No | EVA | |
| rs477636388 | 37 | W>G | No | EVA | |
| rs457576285 | 42 | G>A | No | EVA | |
| rs1115523813 | 46 | P>L | No | EVA | |
| rs461973113 | 49 | L>R | No | EVA | |
| rs441828469 | 50 | A>D | No | EVA | |
| rs476375048 | 52 | P>R | No | EVA | |
| rs463087635 | 54 | C>W | No | EVA | |
| rs439727308 | 56 | R>G | No | EVA | |
| rs454134108 | 58 | M>L | No | EVA | |
| rs440347981 | 58 | M>R | No | EVA | |
| rs475362043 | 59 | A>P | No | EVA | |
| rs455108603 | 61 | L>P | No | EVA | |
| rs438219526 | 64 | V>G | No | EVA | |
| rs469388580 | 68 | L>R | No | EVA | |
| rs432840695 | 74 | A>G | No | EVA | |
| rs464052966 | 75 | F>L | No | EVA | |
| rs447240850 | 81 | L>H | No | EVA | |
| rs478618068 | 84 | C>F | No | EVA | |
| rs433660626 | 107 | Y>S | No | EVA | |
| rs474681620 | 108 | S>C | No | EVA | |
| rs3423094927 | 110 | E>Q | No | EVA | |
| rs437562679 | 114 | E>Q | No | EVA | |
| rs469285759 | 122 | E>K | No | EVA | |
| rs445943886 | 127 | H>P | No | EVA | |
| rs439262880 | 140 | C>W | No | EVA | |
| rs432172108 | 146 | C>* | No | EVA | |
| rs476863605 | 151 | K>N | No | EVA | |
| rs466724124 | 169 | K>N | No | EVA | |
| rs385561685 | 198 | T>I | No | EVA | |
| rs463262004 | 239 | R>S | No | EVA | |
| rs208581540 | 242 | R>Q | No | EVA | |
| rs470950068 | 264 | P>A | No | EVA | |
| rs454456593 | 264 | P>Q | No | EVA | |
| rs436460849 | 272 | T>A | No | EVA | |
| rs436460849 | 272 | T>P | No | EVA | |
| rs459219252 | 296 | Q>E | No | EVA |
No associated diseases with Q2YDC9
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
3 GO annotations of molecular function
| Name | Definition |
|---|---|
| DNA binding | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). |
| enzyme binding | Binding to an enzyme, a protein with catalytic activity. |
| metal ion binding | Binding to a metal ion. |
5 GO annotations of biological process
| Name | Definition |
|---|---|
| activation of cysteine-type endopeptidase activity involved in apoptotic process | Any process that initiates the activity of the inactive enzyme cysteine-type endopeptidase in the context of an apoptotic process. |
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| positive regulation of apoptotic process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. |
| positive regulation of hematopoietic stem cell proliferation | Any process that activates or increases the frequency, rate or extent of hematopoietic stem cell proliferation. |
| regulation of hematopoietic progenitor cell differentiation | Any process that modulates the frequency, rate or extent of hematopoietic progenitor cell differentiation. |
1 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q16342 | PDCD2 | Programmed cell death protein 2 | Homo sapiens (Human) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MASESAGPAE | LGFVEAAPSW | RLRSEQFPSK | VGGRPAWLSA | AGLPGPPELA | CPLCGRPMAF |
| 70 | 80 | 90 | 100 | 110 | 120 |
| LLQVYAPLPG | RADAFHRCLF | LFCCRTPPCC | CGLRVFRNQL | PRQNDFYSYE | PPSEDPPSET |
| 130 | 140 | 150 | 160 | 170 | 180 |
| GESVYLHLKS | GAHLCRVCGC | SGPKRCSRCH | KAHYCSKEHQ | SLDWRLGHKQ | ACAQTDNLDN |
| 190 | 200 | 210 | 220 | 230 | 240 |
| IVPDHNFLFP | EFEIVIETED | EIMPEVVERD | DESEIIGTMG | EAHEEELESM | AKHESKEDRI |
| 250 | 260 | 270 | 280 | 290 | 300 |
| FRKFKTKISL | EPEQILRYGR | GIAPLWISGE | NTPKEKDIPD | CPCGAKRLFE | FQVMPQLLNY |
| 310 | 320 | 330 | 340 | ||
| LKADRLGRSV | DWGVLAIFTC | AESCKLGIGY | TEEFVWKQDI | TDAA |